Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of eribulin with or without SB3 (trastuzumab biosimilar) in HER2-overexpressed recurrent or stage IV breast cancer
KCT0004248Phase 2Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin, trastuzumab-dttb in breast cancer, sponsored by Daewoong Pharmaceutical. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
eribulintrastuzumab-dttb
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0004248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004248.